Abstract
Purpose :
To investigate the impact of the instillation timing of carteolol hydrochloride/latanoprost combination ophthalmic solution （LCFC）, in the morning or at night, in patients with glaucoma on the diurnal variations of IOP and on the circulatory system, comparing with timolol/latanoprost combination ophthalmic solution （LTFC） as a control.
Methods :
Twenty-two eyes of 22 patients with POAG or OH on monotherapy with a prostaglandin ophthalmic solution were included. They were randomly assigned to either a group of switching from LCFC to LTFC or a group of switching from LTFC to LCFC. Both drugs were administered at 8 p.m. every night for 2 months each.
At the start of evaluation, the diurnal variation in IOP, vital signs (pulse rate, blood pressure), fluorescein corneal staining test and ophthalmological subjective symptoms at 2 months after the start of administration of each ophthalmic solution were evaluated. The adverse events during the evaluation period were also surveyed.
Results :
The diurnal variation in IOP at 2 months after the start of evaluation period showed a similar transition in the LCFC group and the LTFC group, with a maximum value of 16.21 mmHg and 16.55 mmHg at a.m. 4:00 and a minimum value of 13.06 mmHg and 12.42 mmHg at p.m. 4:00, respectively. There were no differences in the range of the diurnal variation and the changes from the start of evaluation.
For the diurnal variation in pulse rate at 2 months after the start of evaluation period, there were significant differences in the changes from the start of evaluation, i.e., -0.8 and -4.3 at 22:00, -2.6 and -7.0 at 2:00, -3.1 and -7.1 at 4:00, and -3.7 and -8.0 at 6:00 in the LCFC group and the LTFC group, respectively.
No adverse events with a causal relationship with the treatment occurred in the both groups.
Conclusions :
The IOP-lowering effect was equivalent in the diurnal variation of IOP at 2 months after the start of the administration in the LCFC group and the LTFC group. The transitional changes were similar, showing the maximum IOP at a.m. 4:00. For the diurnal variation at 2 months after the start of the administration, the pulse rate is less affected in the LCFC group, and the safety of night instillation was shown.
This is a 2021 ARVO Annual Meeting abstract.